tiprankstipranks
Advertisement
Advertisement
HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsHRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
Premium
Ratings
Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
3M ago
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
Premium
Company Announcements
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
3M ago
Heron Therapeutics Reports Strong Q3 2025 Revenue Growth
PremiumCompany AnnouncementsHeron Therapeutics Reports Strong Q3 2025 Revenue Growth
5M ago
Heron Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Heron Therapeutics’ Earnings Call: Growth Amid Challenges
5M ago
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
Premium
Ratings
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
5M ago
Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M
PremiumThe FlyHeron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M
5M ago
HRTX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
HRTX Upcoming Earnings Report: What to Expect?
5M ago
Heron Therapeutics Appoints Thomas Cusack to Board
Premium
Company Announcements
Heron Therapeutics Appoints Thomas Cusack to Board
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100